Department of Endocrinology, Diabetes and Metabolic Diseases, Rouen University Hospital, Rouen, France.
Department of Endocrinology, Diabetes and Metabolic Diseases, Hôpital de la Cavale Blanche, Brest, France.
Ann Endocrinol (Paris). 2021 Feb;82(1):43-51. doi: 10.1016/j.ando.2020.12.002. Epub 2020 Dec 3.
Our understanding of vitamin D has improved considerably in recent years. The role of vitamin D in preventing osteoporotic fractures is now well-established. However, an important controversy has emerged in the last decade concerning the effects of the active form of vitamin D (1,25-dihydroxy-vitamin D) on tissues other than bone (non-classical effects). The demonstration that the vitamin D receptor (VDR) is ubiquitously, expressed combined with increasing observational data supporting a relationship between the level of 25-hydroxy-vitamin D in the serum and chronic metabolic disorders, cardiovascular disease and neoplasms, have led to its redefinition as a steroid hormone and the proposal of its use in preventing and/or treating those diseases. This article is an update on the different non-bone or non-classical effects of "vitamin-hormone D", and its potential preventive or therapeutic role in certain diseases, however, this review is not exhaustive. The different modalities of substitution or supplementation proposed in France by the Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO) are also summarised.
近年来，我们对维生素 D 的认识有了很大的提高。维生素 D 在预防骨质疏松性骨折中的作用现在已经得到充分证实。然而，在过去十年中，关于维生素 D 的活性形式（1,25-二羟维生素 D）对骨骼以外的组织的影响（非经典作用）出现了一个重要的争议。维生素 D 受体 (VDR) 广泛表达的证明，加上越来越多的观察数据支持血清 25-羟维生素 D 水平与慢性代谢紊乱、心血管疾病和肿瘤之间的关系，已经导致它被重新定义为一种类固醇激素，并提出将其用于预防和/或治疗这些疾病。本文更新了“维生素激素 D”的不同非骨骼或非经典作用及其在某些疾病中的潜在预防或治疗作用，但这并不是详尽无遗的。法国骨质疏松研究和信息组 (GRIO) 提出的不同替代或补充方式也进行了总结。
